Osteosarcoma
Background[1]
- Most common primary pediatric bone tumor
- 3% of all childhood cancers
- Around two-thirds of those diagnosed with non-metastatic disease under the age of 40 will be long-term survivors or cured of the disease with appropriate treatment
- Survival is less than 20% with metastatic disease
- One-fifth will have metastases at presentation
- Most common metastatic site is lung followed by bone
- Bimodal as it peaks in early adolescence and over the age of 65
Pathophysiology
- Overproduction of osteoid and immature bone by malignant osteoblasts
Clinical Features
- Often an adolescent during a growth spurt
- Bone pain for several months that worsens with activity and is more painful at night
- Absence of constitutional symptoms (e.g., fevers, weight loss, night sweats, and decreased appetite are typically absent)
- Large soft tissue mass on exam that is tender to palpation
- Occurs at metaphysis of long bones
- Most commonly at the distal femur followed by the proximal tibia
- Less frequently presents as pathological fracture
- Risk factors include prior cancer treatment, Paget disease of bone, benign bone disease, Hereditary Retinoblastoma or Li-Fraumeni syndrome
Differential Diagnosis
Bone tumors and their mimics
Malignant
- Multiple myeloma
- Chondrosarcoma
- Paget disease
- Osteosarcoma
- Adamantinoma
- Chordoma
- Primary bone lymphoma
- Fibrosarcoma
- Myosarcoma
Benign
- Giant cell tumor
- Chrondroblastoma
- Enchondroma
- Langerhans cell histiocytosis of bone
- Osteoblastoma
- Osteochondroma
- Osteoid osteoma
Other
Evaluation
- X-ray
- "Sunburst" pattern on X-ray
- This pattern describes a lytic lesion with periosteal reaction and cortical disruption at or near the metaphysis
- "Sunburst" pattern on X-ray
- Codman triangle
- New subperiosteal bone formed when the periosteum is raised away from the bone
- Codman triangle
- Elevated alkaline phosphatase
- Elevated LDH
- High LDH associated with poor outcome
- Elevated ESR
- MRI and biopsy for definitive diagnosis
Management
- Pain control
- Limb sparing surgery or amputation, if needed
- Depends on location and extent of the primary tumor
- Neoadjuvant chemotherapy
- Response is a major prognostic factor
- MAP therapy (methotrexate, doxorubicin, cisplatin) often regimen of choice for non-metastatic disease
- No standard approach if metastatic
- Typically, radiation resistant
- If at base of skull or sacrum can consider intensity-modulated radiation therapy
Disposition
- Home if patient can get expedited follow up
- Admission and work-up if suspected delay in outpatient care
References
- ↑ Niederhuber, John E., et al. “Sarcomas.” Abeloff's Clinical Oncology E-Book. Elsevier Health Sciences, 2019, pp. 1604 – 1654.e8.